Back to Search
Start Over
Nanoparticles of folic acid-methyl-β-cyclodextrin (FA-MβCD)/adamantane-albumin exhibit enhanced antitumor activity compared with FA-MβCD alone.
- Source :
-
FEBS open bio [FEBS Open Bio] 2023 Feb; Vol. 13 (2), pp. 233-245. Date of Electronic Publication: 2022 Dec 26. - Publication Year :
- 2023
-
Abstract
- Supramolecular drug carriers are a promising approach for delivering anticancer drugs with high blood retention after administration. We previously synthesized folic acid-modified methyl-β-cyclodextrin (FA-MβCD) as an anticancer drug. FA-MβCD has a selective autophagy-mediated antitumor effect on folic acid receptor (FR)-expressing cancer cells. Here, we enhanced the antitumor effect and safety of FA-MβCD by preparing a supramolecular nanoparticle formulation of FA-MβCD via host-guest interactions using an adamantane conjugate with human serum albumin (Ad-HSA). The Ad-HSA/FA-MβCD supramolecular complex prolonged the blood retention of FA-MβCD and improved its antitumor effect and safety after intravenous administration in tumor-bearing mice xenografted with FR-expressing cancer cells. These results suggest that the supramolecular technique using Ad-HSA is a promising approach for the delivery of CD-based anticancer drugs.<br /> (© 2022 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
Details
- Language :
- English
- ISSN :
- 2211-5463
- Volume :
- 13
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- FEBS open bio
- Publication Type :
- Academic Journal
- Accession number :
- 36537756
- Full Text :
- https://doi.org/10.1002/2211-5463.13540